FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江蘇恒瑞醫藥股份有限公司 呈交日期： 2026年1月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 | 否 | | | | 證券代號 (如上市) | 600276 | 說明 | A股（於上海證券交易所上市） | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | ...

Core Viewpoint - The report highlights the current AH premium rates of various stocks, indicating significant disparities between H-shares and A-shares, with some stocks showing extremely high premiums while others exhibit negative premiums. Group 1: Top AH Premium Rates - Northeast Electric (00042) has the highest AH premium rate at 800.00% [1] - Zhejiang Shibao (01057) follows with a premium rate of 351.95% [1] - Beijing Machinery (00187) ranks third with a premium rate of 269.91% [1] - The top ten stocks with high premium rates include companies like Hongye Futures (03678) and Sinopec Oilfield Services (01033) with premium rates of 264.44% and 263.64% respectively [2] Group 2: Bottom AH Premium Rates - Contemporary Amperex Technology (03750) has the lowest AH premium rate at -12.95% [3] - China Merchants Bank (03968) and Heng Rui Medicine (01276) follow with rates of -3.26% and -2.69% respectively [3] - Other companies in the bottom tier include Wu Chai Power (02338) and Midea Group (00300) with positive but low premiums of 7.63% and 8.11% [3] Group 3: Top Deviation Values - Andeli Juice (02218) has the highest deviation value at 28.13% [4] - Goldwind Technology (02208) and Junshi Biosciences (01877) follow with deviation values of 23.37% and 16.76% respectively [4] - Other notable companies include Beijing Machinery (00187) with a deviation value of 12.63% [4] Group 4: Bottom Deviation Values - Zhejiang Shibao (01057) has the lowest deviation value at -39.21% [5] - Northeast Electric (00042) and Yangtze Optical Fibre and Cable (06869) follow with deviation values of -38.76% and -35.09% respectively [5] - Other companies with negative deviation values include Nanhua Futures (02691) and Chenming Paper (01812) [5]

Company News - China Power (02380.HK) expects a total consolidated electricity sales volume of 10.73105 million MWh by December 2025, a decrease of 2.31% year-on-year; the total annual electricity sales volume is approximately 126 million MWh, down 1.27% year-on-year [2] - Harbin Electric (01133.HK) anticipates a net profit attributable to shareholders of approximately RMB 2.65 billion for the fiscal year 2025, compared to RMB 1.686 billion in the previous year, mainly due to increased operating revenue and improved product profitability [2] - Singularity Guofeng (01280.HK) has entered into a GPU distribution cooperation agreement with Muxi Co., aiming to enter the domestic AI computing power market [2] - Dongyang Sunshine Pharmaceutical (06887.HK) has signed a strategic cooperation agreement with Shenzhen Jingtai to establish a joint venture for building an AI-driven drug research and development platform [2] - Weisheng Pharmaceutical-B (02561.HK) has received approval from the National Medical Products Administration for the marketing authorization application of injectable Long Pei growth hormone [2] - Kintor Pharmaceutical-B (02171.HK) issued a profit warning, expecting a net loss for 2025 to be reduced to no more than approximately RMB 120 million [2] - Zhaoke Ophthalmology-B (06622.HK) is advancing the commercialization process of BRIMOCHOL PF for treating presbyopia in Singapore and Vietnam through partnerships with AFT and Qianshou [2] Additional Company Developments - Heng Rui Medicine (01276.HK) has received a clinical trial approval notice for SHR-1049 injection [3] - Baolong Real Estate (01238.HK) has had its bond restructuring plan approved by the relevant bondholders' meeting [3] Strategic Partnerships - Yabo Technology Holdings (08279.HK) has entered into a technical service agreement with Hong Kong Gold Exchange Limited [4] - Future Data Group (08229.HK) has signed a strategic cooperation framework agreement with Linghe Culture [4] - Howey Group (00501.HK) plans to invest up to USD 50 million to subscribe for shares in Aixin Yuanzhi's initial public offering [4] Buyback Activities - Xiaomi Group-W (01810.HK) repurchased 3.9872 million shares for HKD 140 million, with a repurchase price ranging from HKD 35.04 to HKD 35.22 [5] - China Metallurgical Group (01618.HK) repurchased 9.011 million shares for HKD 16.9299 million, with a repurchase price of HKD 1.87 to HKD 1.88 [5] - Geely Automobile (00175.HK) repurchased 4.401 million shares for HKD 72.952 million, with a repurchase price ranging from HKD 16.43 to HKD 16.65 [6] - Reshape Energy (02570.HK) completed the placement of a total of 4.536 million placement shares, raising approximately HKD 258 million [6] - Kintor Pharmaceutical-B (09939.HK) saw an increase of 4.7 million shares by Chairman Tong Youzhi [6]

北京商报讯(记者王寅浩宋雨盈)1月26日，恒瑞医药（600276）发布公告称，公司收到国家药品监督管 理局核准签发关于SHR-1049注射液的《药物临床试验批准通知书》，将于近期开展临床试验。根据公 告，SHR-1049注射液是创新型抗肿瘤药物，拟用于治疗晚期实体瘤，目前国内外尚无同类药物获批上 市。 ...

| 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | 交易日期 | 证券简称 | 证券代码 | 卖出营业部 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 华泰证券股份有限 公司总部 | 圍) 看限公司 上海 | 2026-01-26 | 恒瑞医药 | 600276 | 5816 | 100 | 58.16 | 1月26日，恒瑞医药大宗交易成交100万股，成交额5816万元，占当日总成交额的1.35%，成交价58.16元，较市场收盘价58.16元持平。 ...

免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 每经AI快讯，恒瑞医药1月26日晚间发布公告称，近日，江苏恒瑞医药股份有限公司收到国家药品监督 管理局核准签发关于SHR-1049注射液的《药物临床试验批准通知书》，将于近期开展临床试验。 每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 （记者 王晓波） ...

Core Viewpoint - Heng Rui Medicine (600276)(01276) has received approval from the National Medical Products Administration for the clinical trial of SHR-1049 injection, an innovative anti-tumor drug developed by the company, aimed at treating advanced solid tumors [1] Group 1: Drug Development - SHR-1049 injection is a self-developed innovative anti-tumor drug by the company [1] - The drug is intended for the treatment of advanced solid tumors [1] - Currently, there are no similar drugs approved for marketing domestically or internationally [1] Group 2: Financial Investment - The cumulative research and development investment for the SHR-1049 injection project is approximately 26 million yuan (unaudited) [1]

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-012 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 剂 型：注射剂 申请事项：临床试验 受 理 号：CXSL2500956 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 11 月 7 日受理的 SHR-1049 注射液符合药品注册的有关要求，同意本品开展单 药在晚期实体瘤中的临床试验。 二、药物的其他情况 SHR-1049 注射液是公司自主研发的创新型抗肿瘤药物，拟用于治疗晚期实 体瘤。经查询，目前国内外尚无同类药物获批上市。截至目前，SHR-1049 注射 液相关项目累计研发投入约为 2,600 万元(未经审计)。 三、风险提示 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）收到国家药品监督 管理局（以下简称"国家药监局"）核准签发关于 SHR-1049 注射液的《药物临 床试验批准通知书》，将于近期开展临床试验。现将相关情况公告如下： 一、药物的基本情况 ...

格隆汇1月26日丨恒瑞医药(01276.HK)发布公告，近日，公司收到国家药监局核准签发关于SHR-1049注 射液的《药物临床试验批准通知书》，将于近期开展临床试验。SHR-1049注射液是公司自主研发的创 新型抗肿瘤药物，拟用于治疗晚期实体瘤。经查询，目前国内外尚无同类药物获批上市。 ...

每经AI快讯，1月26日，恒瑞医药（600276）(600276.SH)公告称，公司收到国家药监局核准签发关于 SHR-1049注射液的《药物临床试验批准通知书》，同意开展单药在晚期实体瘤中的临床试验。SHR- 1049注射液是公司自主研发的创新型抗肿瘤药物，拟用于治疗晚期实体瘤。经查询，目前国内外尚无同 类药物获批上市。 ...